Gilead Sciences (NASDAQ:GILD) has received a positive recommendation for approval from European regulators for its drug seladelpar for the treatment of primary biliary cholangitis, or PBC, a rare ...

Topline data were announced from a phase 2/3 trial evaluating tovecimig plus paclitaxel in patients with advanced biliary tract cancer.